Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377018520> ?p ?o ?g. }
- W4377018520 endingPage "114891" @default.
- W4377018520 startingPage "114891" @default.
- W4377018520 abstract "The aim of this study was to analyze and compare the therapeutic effects of 131I-caerin 1.1 and 131I-c(RGD)2 on TE-1 esophageal cancer cell xenografts. (1) The in vitro antitumor effects of the polypeptides caerin 1.1 and c(RGD)2 were verified by MTT and clonogenic assays. 131I-caerin 1.1 and 131I-c(RGD)2 were prepared by chloramine-T (Ch-T) direct labeling, and their basic properties were measured. The binding and elution of 131I-caerin 1.1, 131I-c(RGD)2, and Na131I (control group) in esophageal cancer TE-1 cells were studied through cell binding and elution assays. (2) The antiproliferative effect and cytotoxicity of 131I-caerin 1.1, 131I-c(RGD)2, Na131I, caerin 1.1 and c(RGD)2 on TE-1 cells were detected by Cell Counting Kit-8 (CCK-8) assay. (3) A nude mouse esophageal cancer (TE-1) xenograft model was established to study and compare the efficacy of 131I-caerin 1.1 and 131I-c(RGD)2 in internal radiation therapy for esophageal cancer. (1) Caerin 1.1 inhibited the in vitro proliferation of TE-1 cells in a concentration-dependent manner, with an IC50 of 13.00 µg/mL. The polypeptide c(RGD)2 had no evident inhibitory effect on the in vitro proliferation of TE-1 cells. Therefore, the antiproliferative effects of caerin 1.1 and c(RGD)2 on esophageal cancer cells were significantly different (P < 0.05). The clonogenic assay showed that the clonal proliferation of TE-1 cells decreased as the concentration of caerin 1.1 increased. Compared with the control group (drug concentration of 0 µg/mL), the caerin 1.1 group showed significantly lower clonal proliferation of TE-1 cells (P < 0.05). (2) The CCK-8 assay showed that 131I-caerin 1.1 inhibited the in vitro proliferation of TE-1 cells, while 131I-c(RGD)2 had no evident inhibitory effect on proliferation. The two polypeptides showed significantly different antiproliferative effects on esophageal cancer cells at higher concentrations (P < 0.05). Cell binding and elution assays showed that 131I-caerin 1.1 stably bound to TE-1 cells. The cell binding rate of 131I-caerin 1.1 was 15.8 % ± 1.09 % at 24 h and 6.95 % ± 0.22 % after 24 h of incubation and elution. The cell binding rate of 131I-c(RGD)2 was 0.06 % ± 0.02 % at 24 h and 0.23 % ± 0.11 % after 24 h of incubation and elution. (3) In the in vivo experiment, 3 days after the last treatment, the tumor sizes of the phosphate-buffered saline (PBS) group, caerin 1.1 group, c(RGD)2 group, 131I group, 131I-caerin 1.1 group, and 131I-c(RGD)2 group were 68.29 ± 2.67 mm3, 61.78 ± 3.58 mm3, 56.67 ± 5.65 mm3, 58.88 ± 1.71 mm3, 14.40 ± 1.38 mm3, and 60.14 ± 0.47 mm3, respectively. Compared with the other treatment groups, the 131I-caerin 1.1 group had significantly smaller tumor sizes (P < 0.001). After treatment, the tumors were isolated and weighed. The tumor weights in the PBS group, caerin 1.1 group, c(RGD)2 group, 131I group, 131I-caerin 1.1 group, and 131I-c(RGD)2 group were 39.50 ± 9.54 mg, 38.25 ± 5.38 mg, 38.35 ± 9.53 mg, 28.25 ± 8.50 mg, 9.50 ± 4.43 mg, and 34.75 ± 8.06 mg, respectively. The tumor weights in the 131I-caerin 1.1 group were significantly lighter than those in the other groups (P < 0.01). 131I-caerin 1.1 has tumor-targeting properties, is capable of targeted binding to TE-1 esophageal cancer cells, can be stably retained in tumor cells, and has an evident cytotoxic killing effect, while 131I-c(RGD)2 has no evident cytotoxic effect. 131I-caerin 1.1 better suppressed tumor cell proliferation and tumor growth than pure caerin 1.1, 131I-c(RGD)2, and pure c(RGD)2." @default.
- W4377018520 created "2023-05-19" @default.
- W4377018520 creator A5001577023 @default.
- W4377018520 creator A5003030968 @default.
- W4377018520 creator A5003098842 @default.
- W4377018520 creator A5019559491 @default.
- W4377018520 creator A5035518500 @default.
- W4377018520 creator A5041479429 @default.
- W4377018520 creator A5042195576 @default.
- W4377018520 creator A5044460901 @default.
- W4377018520 creator A5055905289 @default.
- W4377018520 creator A5061682647 @default.
- W4377018520 creator A5066597852 @default.
- W4377018520 creator A5068377419 @default.
- W4377018520 creator A5070151668 @default.
- W4377018520 creator A5071617647 @default.
- W4377018520 creator A5072923976 @default.
- W4377018520 creator A5075945352 @default.
- W4377018520 creator A5090095788 @default.
- W4377018520 date "2023-08-01" @default.
- W4377018520 modified "2023-10-16" @default.
- W4377018520 title "Experimental study of 131I-caerin 1.1 and 131I-c(RGD)2 for internal radiation therapy of esophageal cancer xenografts" @default.
- W4377018520 cites W2023061736 @default.
- W4377018520 cites W2138209595 @default.
- W4377018520 cites W2147545451 @default.
- W4377018520 cites W2418420084 @default.
- W4377018520 cites W2799402272 @default.
- W4377018520 cites W2887401669 @default.
- W4377018520 cites W3047587264 @default.
- W4377018520 cites W3135912809 @default.
- W4377018520 cites W3159283702 @default.
- W4377018520 cites W3178472217 @default.
- W4377018520 cites W3210887028 @default.
- W4377018520 cites W3212947909 @default.
- W4377018520 cites W4226108510 @default.
- W4377018520 cites W4292261973 @default.
- W4377018520 cites W4309461378 @default.
- W4377018520 doi "https://doi.org/10.1016/j.biopha.2023.114891" @default.
- W4377018520 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37209630" @default.
- W4377018520 hasPublicationYear "2023" @default.
- W4377018520 type Work @default.
- W4377018520 citedByCount "0" @default.
- W4377018520 crossrefType "journal-article" @default.
- W4377018520 hasAuthorship W4377018520A5001577023 @default.
- W4377018520 hasAuthorship W4377018520A5003030968 @default.
- W4377018520 hasAuthorship W4377018520A5003098842 @default.
- W4377018520 hasAuthorship W4377018520A5019559491 @default.
- W4377018520 hasAuthorship W4377018520A5035518500 @default.
- W4377018520 hasAuthorship W4377018520A5041479429 @default.
- W4377018520 hasAuthorship W4377018520A5042195576 @default.
- W4377018520 hasAuthorship W4377018520A5044460901 @default.
- W4377018520 hasAuthorship W4377018520A5055905289 @default.
- W4377018520 hasAuthorship W4377018520A5061682647 @default.
- W4377018520 hasAuthorship W4377018520A5066597852 @default.
- W4377018520 hasAuthorship W4377018520A5068377419 @default.
- W4377018520 hasAuthorship W4377018520A5070151668 @default.
- W4377018520 hasAuthorship W4377018520A5071617647 @default.
- W4377018520 hasAuthorship W4377018520A5072923976 @default.
- W4377018520 hasAuthorship W4377018520A5075945352 @default.
- W4377018520 hasAuthorship W4377018520A5090095788 @default.
- W4377018520 hasBestOaLocation W43770185201 @default.
- W4377018520 hasConcept C109316439 @default.
- W4377018520 hasConcept C117262875 @default.
- W4377018520 hasConcept C121608353 @default.
- W4377018520 hasConcept C126322002 @default.
- W4377018520 hasConcept C153911025 @default.
- W4377018520 hasConcept C185592680 @default.
- W4377018520 hasConcept C202751555 @default.
- W4377018520 hasConcept C2779742542 @default.
- W4377018520 hasConcept C2780783641 @default.
- W4377018520 hasConcept C502942594 @default.
- W4377018520 hasConcept C55493867 @default.
- W4377018520 hasConcept C71924100 @default.
- W4377018520 hasConcept C86803240 @default.
- W4377018520 hasConcept C96232424 @default.
- W4377018520 hasConceptScore W4377018520C109316439 @default.
- W4377018520 hasConceptScore W4377018520C117262875 @default.
- W4377018520 hasConceptScore W4377018520C121608353 @default.
- W4377018520 hasConceptScore W4377018520C126322002 @default.
- W4377018520 hasConceptScore W4377018520C153911025 @default.
- W4377018520 hasConceptScore W4377018520C185592680 @default.
- W4377018520 hasConceptScore W4377018520C202751555 @default.
- W4377018520 hasConceptScore W4377018520C2779742542 @default.
- W4377018520 hasConceptScore W4377018520C2780783641 @default.
- W4377018520 hasConceptScore W4377018520C502942594 @default.
- W4377018520 hasConceptScore W4377018520C55493867 @default.
- W4377018520 hasConceptScore W4377018520C71924100 @default.
- W4377018520 hasConceptScore W4377018520C86803240 @default.
- W4377018520 hasConceptScore W4377018520C96232424 @default.
- W4377018520 hasFunder F4320321001 @default.
- W4377018520 hasFunder F4320334898 @default.
- W4377018520 hasFunder F4320335480 @default.
- W4377018520 hasLocation W43770185201 @default.
- W4377018520 hasLocation W43770185202 @default.
- W4377018520 hasOpenAccess W4377018520 @default.
- W4377018520 hasPrimaryLocation W43770185201 @default.
- W4377018520 hasRelatedWork W1974029411 @default.
- W4377018520 hasRelatedWork W2077266389 @default.